Content » Vol 43, Issue 1

Special report

Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: Evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity

Jörgen Borg, Anthony B. Ward, Jörg Wissel, Jai Kulkarni, Mohamed Sakel, Per Ertzgaard, Per Åkerlund, Iris Reuter, Christoph Herrmann, Lalith Satkunam , Theodore Wein, Isabelle Girod, Nicola Wright, on behalf of the BEST Study Group
DOI: 10.2340/16501977-0663

Abstract

Objective: This report describes the design of a study aiming to provide evidence for the extended use of botulinum toxin A in focal post-stroke upper and lower limb spasticity and to evaluate the impact of incorporating botulinum toxin treatment into the rehabilitation of patients with spasticity.
Design: International, prospective, randomized, double-blind, placebo-controlled study with an open-label extension.
Methods: Approximately 300 adults with a stroke occurring ≥ 3 months before screening, presenting with symptoms and signs of an upper motor neuron syndrome and focal spasticity-related functional impairment, were randomized to botu­linum toxin (BOTOX®, Allergan Inc.) + standard care or placebo + standard care. Study medication was administered at baseline and again at Week 12 if required, with follow-up to 52 weeks. The primary endpoint was the number of patients who achieved their investigator-rated principal active functional goal (as measured by Goal Attainment Scaling), at 10 weeks after the second injection (Weeks 22−34) or at the 24-week visit if no second injection was administered. Secondary endpoints included changes from baseline in level of goal achievement, health-related quality of life and resource utilization.
Conclusion: Botulinum toxin A Economic Spasticity Trial (BEST) will provide information regarding clinical and cost-effectiveness of botulinum toxin + standard care vs standard care alone in patients with upper and/or lower limb post-stroke spasticity typically seen in clinical practice.
Trial registration: ClinicalTrials.gov number NCT­00549783.

Lay Abstract

Comments

Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors. You need to login/create an account to comment on articles. Click here to login/create an account.
Advertisement